Hema Now
In this episode of Hema Now, we speak with Cecilia Karlström about advances in rare and complex haematological disorders. She discusses the evolving understanding of platelet refractoriness and transfusion support, the challenges in diagnosing systemic mastocytosis, and how targeted therapies are reshaping outcomes in rare blood diseases. The conversation also explores the growing role of precision medicine, multidisciplinary care, and future priorities in hematology research.
Spotify | Apple | Amazon Music | YouTube | Download MP3
Cecilia Karlström is a Consultant Haematologist at Karolinska University Hospital, Stockholm and an affiliated researcher at Karolinska Institutet, Stockholm, Sweden. Her clinical and research interests span myeloid malignancies, systemic mastocytosis, transfusion medicine, and rare haematological disorders. Karlström has contributed significantly to advancing our understanding of platelet transfusion support in hematology patients and remains actively involved in improving care pathways for patients with rare and complex blood diseases.
Timestamps:
00:00 – Introduction
01:21 – Career inspiration in hematology origins
02:43 – Evolution of platelet refractoriness management
03:39 – Current state systemic mastocytosis care
05:03 – Diagnosing systemic mastocytosis challenges today
07;26 – Impact of targeted therapies mastocytosis
07:26 – Future precision medicine opportunities hematology
09:00 – Multidisciplinary care improving patient outcomes
10:25 – Improving equity rare disease access
11:43 – Exciting research areas haematological disorders
13:14 – Three wishes future hematology advances
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Keywords: Hematology research, hematology, multidisciplinary care, myeloid malignancies, platelet refractoriness, precision medicine, rare diseases, systemic mastocytosis, transfusion medicine.
